Dr Hitesh Mistry, Principal Consultant for Physiomics was interviewed by BioNeex on Cancer drug licensing: How to use your data to make yourself an attractive partner.
Please click here to watch the interview in full....
Oxford, UK, 21 February 2019: The Board of Physiomics Plc, a provider of technology- based solutions to predict the effects of cancer treatment regimens for the biopharma industry (AIM: PYC), today announces its financial results for the six months ended 31 December 2018.
Click here to read in full.
...
Physiomics plc (AIM: PYC), is pleased to announce that one of its long-term consultants and collaborators, Dr Hitesh Mistry, has been appointed to the editorial board of the International Journal of Radiation Oncology-Biology-Physics (RedJournal).
Click here to read in full....
Physiomics plc (AIM: PYC), is pleased to announce that it will be attending the Biotech Showcase partnering conference in San Francisco from 7-9 January 2019 during the JP Morgan Healthcare Conference week. During this week, many of the world’s most successful biotech and pharmaceutical companies are present in San Francisco to meet with prospective clients and partners. Over three thousand attendees are expected to participate...
Physiomics plc (AIM: PYC), is pleased to announce that it has entered into a strategic collaboration with the Medicines Discovery Catapult. Physiomics will be part of the “Virtual R&D” network of advisors and available to provide advice to the many small biotechnology companies supported by Medicines Discovery Catapult.
Click here to read in full.
...
Physiomics plc (Oxford, UK) is pleased to announce that, following a successful collaboration this year and pursuant to the Master Services Agreement signed with Merck, a leading science and technology company, in November 2017, it has agreed with its client a program of work for the next calendar year.
Click here to read in full....
The Company held its Annual General Meeting at its offices in Oxford on 20th November 2018 and is pleased to announce that all resolutions put to shareholders were passed.
Please click here to read in full....
Physiomics plc is pleased to announce that it will be attending the 30th EORTC-NCI-AACR SYMPOSIUM in Dublin 13-16 November 2018. The European Organisation for
Research and Treatment of Cancer (“EORTC”) acts as a hub for a network of over 930 institutions in 30 countries focused on translational and clinical cancer research.
The Symposium is co-hosted by EORTC, the National Cancer Institute (NCI) and the American Association for...
Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has today posted to shareholders
its Annual Report for the financial year ended 30th June 2018 and
a Circular in relation to its forthcoming Annual General Meeting
Please click here to read in full....
